Antony A. Riley - Apr 1, 2023 Form 4 Insider Report for Forte Biosciences, Inc. (FBRX)

Signature
/s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact
Stock symbol
FBRX
Transactions as of
Apr 1, 2023
Transactions value $
-$3,273
Form type
4
Date filed
4/4/2023, 08:18 PM
Previous filing
Feb 27, 2023
Next filing
Jul 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FBRX Common Stock Options Exercise $0 +9.38K +75.04% $0.00 21.9K Apr 1, 2023 Direct F1, F2
transaction FBRX Common Stock Tax liability -$3.27K -3.24K -14.82% $1.01 18.6K Apr 1, 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FBRX Restricted Stock Units Options Exercise $0 -9.38K -6.25% $0.00 141K Apr 1, 2023 Common Stock 9.38K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock.
F2 Includes 1,429 shares of Common Stock acquired January 3, 2022 under Forte Biosciences, Inc.'s 2017 Employee Stock Purchase Plan.
F3 On April 1, 2023, the Reporting Person's RSUs vested. The closing price of Forte Biosciences, Inc.'s Common Stock on March 31, 2023 was the settlement price used to calculate the shares withheld.
F4 Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1.